Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1976 1
1982 2
1983 3
1984 2
1985 5
1986 1
1987 1
1988 4
1989 8
1990 6
1991 7
1992 7
1993 3
1994 12
1995 13
1996 13
1997 13
1998 12
1999 13
2000 16
2001 9
2002 24
2003 28
2004 36
2005 34
2006 37
2007 41
2008 48
2009 47
2010 48
2011 50
2012 56
2013 71
2014 64
2015 54
2016 67
2017 52
2018 55
2019 51
2020 59
2021 53
2022 49
2023 50
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

1,092 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial.
Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV. Kumar P, et al. J Gerontol A Biol Sci Med Sci. 2023 Jan 26;78(1):75-89. doi: 10.1093/gerona/glac135. J Gerontol A Biol Sci Med Sci. 2023. PMID: 35975308 Free PMC article. Clinical Trial.
In prior studies, we identified that deficiency of the intracellular antioxidant glutathione (GSH) could play a role and reported that supplementing GlyNAC (combination of glycine and N-acetylcysteine [NAC]) in aged mice improved GSH deficiency, OxS, mitochondrial fatty-ac …
In prior studies, we identified that deficiency of the intracellular antioxidant glutathione (GSH) could play a role and reported that suppl …
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.
Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TJ 2nd, Murray NG, McCashland T, Reisch JS, Robuck PR; Acute Liver Failure Study Group. Lee WM, et al. Gastroenterology. 2009 Sep;137(3):856-64, 864.e1. doi: 10.1053/j.gastro.2009.06.006. Epub 2009 Jun 12. Gastroenterology. 2009. PMID: 19524577 Free PMC article. Clinical Trial.
BACKGROUND & AIMS: N-acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non-acetaminophen-related acute liver failure. ...
BACKGROUND & AIMS: N-acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non-acetaminophen …
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Cazzola M, et al. Eur Respir Rev. 2015 Sep;24(137):451-61. doi: 10.1183/16000617.00002215. Eur Respir Rev. 2015. PMID: 26324807 Free PMC article. Review.
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD), we have carried out a meta-analysis testing the available evidence that NAC treatment may be effective in …
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obst …
N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.
Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW. Grant JE, et al. JAMA Psychiatry. 2016 May 1;73(5):490-6. doi: 10.1001/jamapsychiatry.2016.0060. JAMA Psychiatry. 2016. PMID: 27007062 Clinical Trial.
Data analysis was performed from July 16 to September 9, 2015. INTERVENTIONS: N-acetylcysteine (dosing range, 1200-3000 mg/d) or placebo was administered for 12 weeks. ...Compared with placebo, N-acetylcysteine treatment was associated with significant improvements …
Data analysis was performed from July 16 to September 9, 2015. INTERVENTIONS: N-acetylcysteine (dosing range, 1200-3000 mg/d) or plac …
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20. N Engl J Med. 2012. PMID: 22607134 Free PMC article. Clinical Trial.
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic pulmonary fibrosis. ...
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic …
Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials.
Lee TM, Lee KM, Lee CY, Lee HC, Tam KW, Loh EW. Lee TM, et al. Aust N Z J Psychiatry. 2021 Feb;55(2):196-206. doi: 10.1177/0004867420952540. Epub 2020 Sep 8. Aust N Z J Psychiatry. 2021. PMID: 32900213
Here, we analyzed the treatment effects of N-acetylcysteine on autism spectrum disorder in randomized controlled trials. ...Regarding Social Responsiveness Scale, the pooled result of two trials showed significant improvement in social awareness after 8-12 weeks of N-ac
Here, we analyzed the treatment effects of N-acetylcysteine on autism spectrum disorder in randomized controlled trials. ...Regarding …
Efficacy and Safety of N-Acetylcysteine for Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
Zhang L, Xiong Y, Du L. Zhang L, et al. Biomed Res Int. 2022 Jun 26;2022:9133777. doi: 10.1155/2022/9133777. eCollection 2022. Biomed Res Int. 2022. PMID: 35795313 Free PMC article. Retracted. Clinical Trial.
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis are associated with poor clinical outcomes. N-acetylcysteine (NAC) is a widely used therapeutic option for such patients; however, the clinical efficacy of NAC has not been conclu …
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis are associated with poor clinical outcomes. N- …
Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study.
Nabi T, Nabi S, Rafiq N, Shah A. Nabi T, et al. Saudi J Gastroenterol. 2017 May-Jun;23(3):169-175. doi: 10.4103/1319-3767.207711. Saudi J Gastroenterol. 2017. PMID: 28611340 Free PMC article. Clinical Trial.
To date, there is no established treatment for non-acetaminophen-induced acute liver failure (NAI-ALF) other than liver transplantation, and little is known about the use of N-acetylcysteine (NAC) in NAI-ALF. A randomized case control study was conducted with the aim to de …
To date, there is no established treatment for non-acetaminophen-induced acute liver failure (NAI-ALF) other than liver transplantation, and …
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Rogliani P, et al. Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y. Respir Res. 2019. PMID: 31133026 Free PMC article.
Considering the inconsistent evidence resulting from the pivotal studies on mucolytic/antioxidant agents tested in chronic obstructive pulmonary disease (COPD), and the recent publication of Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD (RESTORE) s …
Considering the inconsistent evidence resulting from the pivotal studies on mucolytic/antioxidant agents tested in chronic obstructive pulmo …
N-Acetylcysteine Use in Non-Acetaminophen-Induced Acute Liver Failure.
McPheeters CM, VanArsdale VM, Weant KA. McPheeters CM, et al. Adv Emerg Nurs J. 2016 Jul-Sep;38(3):183-9. doi: 10.1097/TME.0000000000000116. Adv Emerg Nurs J. 2016. PMID: 27482990 Review.
The efficacy of N-acetylcysteine in the treatment of acute liver failure from causes other than acetaminophen toxicity was evaluated. The efficacy of N-acetylcysteine in non-acetaminophen-induced acute liver failure is limited to specific patient populations. ...
The efficacy of N-acetylcysteine in the treatment of acute liver failure from causes other than acetaminophen toxicity was evaluated. …
1,092 results